We’re launching Lyria 3.5 in Google Flow Music, with advances across musicality, lyrics, vocals, and creative control
deepmind.google·6d ago
AI Engineering
MIT Technology Review·5d ago·5 min read
Montana’s plan to become an experimental medical hub just pushed forward
TL;DR
Montana has launched a new program allowing biotech companies to sell experimental drugs after limited testing, making access available to anyone who can pay. This unique legislation aims to facilitate treatments for rare diseases and longevity enthusiasts, but raises concerns about safety and oversight.
✦ Why It Matters
Consider the implications of unregulated drug access and advocate for responsible oversight in your area.
Key Takeaways
- Evaluate the implications of Montana's new drug access laws for your projects.
- Consider the ethical aspects of offering unproven treatments.
- Stay informed about FDA regulations regarding experimental drugs.
- Engage with biotech companies interested in Montana's framework.
Full Summary
Montana's recent legislation allows biotech firms to sell experimental drugs to consumers after preliminary testing, with a streamlined application process costing $12,500. Unlike other states, this law permits access to anyone who can pay and provides informed consent, targeting not just terminally ill patients but also those seeking preventive therapies.
The state has established an independent review board, the Montana Experimental Treatment Review Board (ETRB), to evaluate applications, ensuring oversight by qualified medical professionals. While proponents argue this fosters innovation in longevity medicine, critics express concerns about the risks of unproven treatments and the lack of FDA oversight.
Initial applications have already been submitted for drugs targeting conditions like neuropathy and hearing loss, indicating strong interest from biotech companies.